|
|
The Relationship between Serum Lp(a)Level and The Degree of Coronary Artery Disease in Patients with Coronary Heart Disease and T2DM |
Wang Dongdong, Chen Zhaojin |
Department of Clinical Laboratory,988 Hospital of Joint Logistic Support Force,Zhengzhou,Henan 450000 |
|
|
Abstract Objective To investigate the relationship between the level of lipid protein a[Lp(a)] and the degree of coronary artery disease in patients with coronary heart disease(CHD)and type 2 diabetes mellitus(T2DM). Method A total of 123 patients diagnosed with T2DM were selected,110 of whom were confirmed by coronary angiography(CAG)with CHD,and divided into moderate stenosis group(30 cases)and severe stenosis group(80 cases)according to the degree of coronary artery stenosis.According to the range of coronary artery lesions,the patients were divided into single-vessel lesion group(25 cases),double-vessel lesion group(55 cases)and multi-vessel lesion group(30 cases).In addition,30 volunteers with normal coronary artery artery treated in our hospital during the same period were selected as the control group,and the levels of blood lipid,apolipoprotein A1(ApoA1),Apolipoprotein B(ApoB)and Lp(a)in each group were measured. Results Compared with the control group,TG and Lp(a)levels were higher in the CHD with T2DM group,but HDL-C level was lower than that in the control group(P<0.05).The Lp(a)levels in control group,moderate stenosis group and severe stenosis group were(115.20±54.09)mg/L,(158.90±65.12)mg/L and(183.20±55.45)mg/L,with severe stenosis group>moderate stenosis group>control group.Lp(a)levels in control group,single arm group,double arm group and multi-arm lesion group were(115.20±54.09)mg/L,(128.90±68.23)mg/L,(186.47±91.23)mg/L,(261.90±109.47)mg/L.Multibranch lesion group>double-branch lesion group>single-branch lesion group(P<0.05),but there was no significant difference in Lp(a)level between single-branch lesion group and control group(P>0.05).When Lp(a)>147.82mg/L,the AUC of CHD with T2DM was 0.821(0.747-0.881),and the sensitivity and specificity were 77.27% and 83.33%,respectively(P<0.05). Conclusion The level of Lp(a)in CHD patients with T2DM increases with the severity of coronary artery stenosis and the increase of coronary artery number.Lp(a)can be used as an important auxiliary index to determine the severity of coronary artery lesions to assist clinical diagnosis and treatment.
|
Received: 11 April 2023
|
|
|
|
|
[1] 郭雪,卢玉润.三种血清因子与冠心病严重程度的关系及诱发疾病的危险因素分析[J].中华老年心脑血管病杂志,2020,22(10):1050-1053. [2] 张亚男,王思明,于雪,等.三甲胺氧化物与冠心病合并2型糖尿病患者冠状动脉病变情况的相关性分析[J].中华心血管病杂志,2021,49(7):680-686. [3] 郝岩,杨玉林,王勇超,等.术前血清脂蛋白a与急性冠状动脉综合征合并2型糖尿病患者PCI术后血运重建的关系[J].临床心血管病杂志,2022,38(6):471-477. [4] 魏冬,高鹏芝,范吉利,等.CTRP3、Lp(a)对冠心病合并糖尿病PCI术后支架内再狭窄的预测价值[J].分子诊断与治疗杂志,2021,13(8):1365-1368. [5] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华内分泌代谢杂志,2021,37(4):311-398. [6] 郭剑平,匡林华,彭丹萍,等.2型糖尿病伴冠心病患者血糖波动及血清Gal-3对主要不良心血管事件的预测价值[J].中国现代医学杂志,2022,32(23):90-96. [7] 符丽珍,赵勇,易必兴,等.过表达miRχ200a?3p对老年糖尿病合并冠心病大鼠心肌纤维化、心脏功能和免疫炎症反应的影响[J].中国糖尿病杂志,2022,30(12):919-924. [8] 肖诚,于淼.胰高糖素样肽-1受体激动剂在2型糖尿病合并动脉粥样硬化性心血管疾病或高危风险人群中的可能机制及循证证据[J].中华糖尿病杂志,2022,14(12):1348-1354. [9] 王永进,卫娇娜,杜亚坤,等.血浆Hcy、D-D及Fib在2型糖尿病并发冠心病患者中的水平变化及相关性分析[J].检验医学与临床,2022,19(5):691-694. [10] 王玺,刘子暖,丁熠璞,等.脂蛋白(a)与冠脉病变严重程度的相关性分析[J].解放军医学院学报,2021,42(11):1129-1133,1147. [11] 王宇鹏,王宏波,石婷,等.血清HCY及LP(a)的水平与冠心病的严重程度的相关性研究[J].湖南师范大学学报(医学版),2021,18(2):1-3. [12] 徐莉,徐晓.血清25(OH)D、Lp(a)和CTnI水平对慢性阻塞性肺疾病急性加重患者合并冠心病患者早期诊断的临床研究[J].临床肺科杂志,2020,25(1):3-7. [13] 王玺,刘子暖,丁熠璞,等.脂蛋白(a)与冠脉病变严重程度的相关性分析[J].解放军医学院学报,2021,42(11):1129-1133,1147. [14] 王宇鹏,王宏波,石婷,等.血清HCY及LP(a)的水平与冠心病的严重程度的相关性研究[J].湖南师范大学学报(医学版),2021,18(2):1-3. [15] 徐莉,徐晓.血清25(OH)D、Lp(a)和CTnI水平对慢性阻塞性肺疾病急性加重患者合并冠心病患者早期诊断的临床研究[J].临床肺科杂志,2020,25(1):3-7. [16] 王磊,司晔巍,曹秋梅.能谱CT冠状动脉血管成像检查联合血清Lp(a)、Vaspin、Copetin水平检测对急性冠脉综合征的诊断价值[J].国际检验医学杂志,2022,43(20):2446-2451. [17] 张琼. 血浆Lp(a)联合EuroSCORE Ⅱ评分预测老年冠心病PCI术后不良心血管事件的价值研究[J].川北医学院学报,2022,37(7):932-934,946. |
[1] |
Yang Fan, Sun Jun, Yang Dongbo. The Expression and Clinical Significance of Serum PC,hs-CRP and NT-proBNP in Different Coronary Artery Diseases of Coronary Heart Disease[J]. journal1, 2024, 44(2): 18-20. |
[2] |
Hou Bin, Zheng Fangfang. Clinical Value of Atorvastatin Calcium Combined with Fenofibrate in the Treatment of Coronary Atherosclerotic Heart Disease[J]. journal1, 2024, 44(1): 11-14. |
[3] |
. [J]. journal1, 2023, 43(6): 59-61. |
[4] |
. [J]. journal1, 2023, 43(5): 63-64. |
[5] |
. [J]. journal1, 2023, 43(5): 71-72. |
[6] |
. [J]. journal1, 2023, 43(4): 65-66. |
|
|
|
|